Clinical Trial Update: SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) [Phase 2]

View source ↗

Summary

Phase II monotherapy trial of SCH 52365 for first-relapsed anaplastic astrocytoma has completed; the snippet does not provide efficacy or safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Astrocytoma

Drugs mentioned

• SCH 52365

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Astrocytoma | Phase 2 | Status: COMPLETED